Exactech Trustee Alleges Multiple Causes of Action against TPG and others on behalf of Creditors, Including Multiple Unsecured Creditors/Personal Injury Victims Represented by Parker Waichman LLP KEY HIGHLIGHTS Exactech Trustee alleges TPG and others concealed known orthopedic implant defects, delayed recalls and forced bankruptcy in an attempt to evade mounting patient injury claims. Thousands of injured patients, now unsecured creditors, face devastating medical and financial harm tied to rec

Appointments to bolster rapid scaling and execution of Pyxa™ spatial platform BOSTON, Feb. 10, 2026 /PRNewswire/ -- Stellaromics, a pioneer in high-resolution 3D spatial multi-omics, today announced the appointment of Stacie Weninger, PhD, and Steve McPhail to its Board of Directors. These strategic appointments come at a pivotal time for the company as it scales its innovative Pyxa™ technology and expands its footprint in the life sciences sector. "We are incredibly honored to welcome Staci

BELFAST, Northern Ireland, Feb. 10, 2026 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, has entered the Japanese market through a new customer relationship with Shionogi & Co., Ltd. (Shionogi), a major research-driven pharmaceutical company based in Japan. Shionogi will leverage the Cumulus NeuLogiq® Platform to generate objective neurophysiological data for S-8

Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq® Company Adds Additional Acclaim-3 Clinical Trial Site AUSTIN, Texas, Feb. 10, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that IP Australia, the Australian government agency responsible for administering Australia's inte

The new collaboration is expected to accelerate, scale and advance small-molecule discovery and optimization for pharmaceutical and agricultural products REHOVOT, Israel, Feb. 10, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a computational chemistry company focused on AI-driven small-molecule design for the pharmaceutical and agricultural industries, today announced an expanded phase of its collaboration with Google Cloud. Under this new phase, the collaboration will focus on

ST. LOUIS, Feb. 10, 2026 /PRNewswire/ -- Kurtis Cox, 55, calls his recent heart bypass surgery with a new hybrid coronary revascularization (HCR) procedure at Mercy Hospital St. Louis "a miracle." Cox was among the first patients in Missouri to undergo the new HCR procedure and was tossing his giggling 7-year-old son over his head only one month later. Continue Reading An alternative to traditional open-heart surgery, HCR combines the best of traditional bypass surgery and stenting. Post this Ku

PITTSBURGH, Feb. 10, 2026 /PRNewswire/ -- Vanscoy Rare Pharmacy, a leading specialty pharmacy focused on supporting people living with rare conditions, announced today that it has been selected as the exclusive specialty pharmacy provider for Redemplo® (plozasiran), a small interfering RNA (siRNA) medicine, indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease, with an estimated 6,500 people in the U.S. livi

CAMBRIDGE, Mass., Feb. 10, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced a series of AI‑empowered drug discovery collaborations across multiple projects in the fields of

Company advances global neuro-intervention footprint with new CE-marked devices for vasospasm and stroke, and expanded U.S. indications for aspiration catheters. PLANO, Texas, Feb. 10, 2026 /PRNewswire/ -- Vesalio, a global leader in vascular intervention, today announced CE Mark certification and the European commercial launch of two new neurovascular devices: NeVa™ VS, for the treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH), and the NeVa™ 3.0 mm Thrombectomy

Pfizer joins six leading pharma companies helping launch and grow exceptional biotech ventures. BASEL, Switzerland, Feb. 10, 2026 /PRNewswire/ -- BaseLaunch, a platform partnering with scientists and entrepreneurs to launch, fund, and build early biotech ventures, announced today the pharmaceutical giant Pfizer has joined the Basel-based incubator, bringing the total number of leading pharma company partners to seven. Continue Reading Landscape image of the Basel area’s booming biotech research